1 March 2021 - The March 2021 issue of the New Zealand Pharmaceutical Schedule is now available and in effect.

There are several major new/revised listings this month:

• Ivacaftor (Kalydeco) - new medicine
• Empagliflozin (Jardiance) - restriction change
• Empagliflozin with metformin hydrochloride (Jardiamet) - restriction change
• Dimethyl fumarate (Tecfidera) - restriction change
• Fingolimod hydrochloride (Gilenya) - restriction change
• Natalizumab (Tysabri) - restriction change
• Ocrelizumab (Ocrevus) - restriction change
• Teriflunomide (Aubagio) - restriction change
• Glatiramer acetate (Copaxone) - restriction change
• Interferon beta-1a (Avonex) - restriction change
• Interferon beta-1b (Betaferon) - restriction change

Read New Zealand Pharmaceutical Schedule update